Medical and Scientific Publications

Many of the nonconfidential advances in our premier research and development pipeline are shared through an extensive list of peer-reviewed publications and posters presented at international conferences.

Narsoplimab (OMS721) Publications:

Narsoplimab is an investigational product not approved by any regulatory agency.

2022

Narsoplimab, a mannan-binding lectin-associated serine protease-2 inhibitor, for the treatment of adult hematopoietic stem-cell transplantation–associated thrombotic microangiopathy

Khaled SK, Claes K, Goh YT, et al. J Clin Oncol. 2022; epub ahead of print. doi:10.1200/JCO.21.02389.

View on PubMed

Trial design: Phase 3 randomized, double-blind, placebo-controlled study of narsoplimab safety and efficacy in IgA nephropathy (ARTEMIS-IGAN)

Lafayette R, Rovin B, Floege J, et al. Kidney Int Rep. 2022;7(2):S57.

View abstract

2021

Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy

Gavriilaki E, Ho VT, Schwaeble W, et al. Exp Hematol Oncol. 2021;10:57.

View on PubMed

Lectin pathway mediates complement activation by SARS-CoV-2 proteins

Ali YM, Ferrari M, Lynch NJ, et al. Front Immunol. 2021;12:714511.
View on PubMed

Narsoplimab (OMS721) treatment contributes to improvements in organ function in adult patients with high-risk transplant-associated thrombotic microangiopathy

Perales M, Cairo M, Duarte R, et al. HemaSphere. 2021;5(suppl 2):79.
View abstract

Narsoplimab (OMS721), a MASP-2 inhibitor, for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA): Subgroup analyses

Rambaldi A, Claes K, Goh YT, et al. Bone Marrow Transplant. 2021;56:147-149.
View abstract

Clinical pharmacology and population pharmacokinetic/pharmacodynamic modeling of lectin pathway inhibition by narsoplimab (OMS721)

Pullman W, Facius A, Lahu G, Smyth B. Bone Marrow Transplant. 2021;56:300-301.
View abstract

In acute HSCT/BMT-TMA the activation of the lectin pathway induces C5b-9 formation on endothelial cells and favors microvascular thrombosis

Galbusera M, Gastoldi S, Noris M, Bresin E, Benigni A, Remuzzi G. Bone Marrow Transplant. 2021;56:295-297
View abstract

Narsoplimab (OMS721), a MASP-2 inhibitor, for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA)

Khaled SK, Boelens JJ, Cairo MS, et al. Transplantation and Cellular Therapy. 2021;27(3):S24-S26.
View abstract

MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab

Elhadad S, Chapin J, Copertino D, Van Besien K, Ahamed J, Laurence J. Clin Exp Immunol. 2021;203(1):96-104.

View on PubMed

2020

Development of pharmacodynamic assays to assess ex vivo MASP-2 inhibition and their use to characterize the pharmacodynamics of narsoplimab (OMS721) in humans and monkeys

Freeman J, Cummings J, Chuidian M, Dudler T. Blood. 2020;136(suppl 1):26-27.
View abstract

Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab

Rambaldi A, Gritti G, Micò MC, et al. Immunobiology. 2020;225(6):152001.
View on PubMed

Safety, tolerability, and effect of narsoplimab (OMS721), a novel MASP-2 inhibitor for the treatment of IgA nephropathy

Lafayette R, Rovin B, Floege J, et al. Kidney Int Rep. 2020;5(11):2032-2041.
View on PubMed

Inhibition of the lectin pathway of the complement system as a novel approach in the management of IgA vasculitis-associated nephritis

Selvaskandan H, Cheung CK, Dormer J, et al. Nephron. 2020;144(9):453-458.
View on PubMed

Narsoplimab (OMS721) for the treatment of adult hematopoietic stem cell transplant-associated thrombotic microangiopathy

Rambaldi A, Smith M, Whitaker S, Khaled S. Oral presentation at: European Hematology Association Congress; June, 2020; virtual.
View abstract

MASP-2 inhibition as a potential strategy for the management of IgA nephropathy

Barratt J, Lafayette R. Drugs of the Future. 2020;45(6):389-396.
View on journal website

2019

MASP-2 levels following allogeneic hematopoietic stem cell transplantation in adults: correlation with development of a thrombotic microangiopathy and implications for therapy with anti-complement agents

Elhadad S, Van Biesen K, Chapin J, Ahamed J, Laurence J. Poster presented at: American Society of Hematology 2019 Annual Meeting; Dec 7-10, 2019; Orlando, FL.
View Abstract

Absence of the lectin activation pathway of complement ameliorates proteinuria-induced renal injury

Alghadban S, Kenawy HI, Dudler T, Schwaeble WJ, Bunskill NJ. Front Immunol. 2019;10:2238.
View on PubMed

Interim results from an ongoing phase 2 study evaluating the use of a MASP-2 inhibitor for the treatment of IgA nephropathy

Barratt J, Leifke E, Whitaker S, et al. Presented at: European Renal Association-European Dialysis and Transplant Association (ERA-EDTA); June, 2019; Budapest, HU.

View Abstract

2018

Cardioprotection by an anti-MASP-2 antibody in a murine model of myocardial infarction

Clark JE, Dudler T, Marber MS, Schwaeble W. Open Heart. 2018;5(1):e000652.

View on PubMed

Improved survival following OMS721 treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA)

Rambaldi A, Khaled S, Smith M, et al. Presented at: European Hematology Association (EHA); June 15, 2018; Stockholm, Sweden.

View Abstract

2017

The effect of OMS721 on proteinuria in patients with IgA nephropathy

Block G, Whitaker S. Presented at: European Renal Association—European Dialysis and Transplant Association (ERA-EDTA); June 4, 2017; Madrid, Spain.

View Abstract

Maintenance of remission following completion of OMS721 treatment in Patients with IgA nephropathy (IgAN)

Block G, Whitaker S. Presented at: American Society of Nephrology (ASN); November 6, 2017; New Orleans, LA.

View Abstract

Effective treatment of GvHD-associated transplant-associated microangiopathy with a novel inhibitor of the lectin pathway of complement

Caprioli C, Grassi A, Micò C, Rambaldi A. Presented at: EBMT Transplant Complications Working Party – Crash Course on Diagnosis and Treatment of Noninfectious Complications after HCT: October 19-20, 2017; Granada, Spain.

Early results of a phase 2 study using OMS721 in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA)

Khaled SK, Kwong YL, Smith M, Metjian A, Whitaker S. Presented at: American Society of Blood and Marrow Transplantation (ASBMT); February 25, 2017; Orlando, FL.

View Abstract

Dose-finding clinical trial of OMS721 for the treatment of atypical hemolytic uremic syndrome (aHUS) – stage 1 results

Nowicki M, Wiecek A, Massart A, Weekers L, Whitaker S, Miglinas M. Presented at: World Congress of Nephrology (WCN); April 21-25, 2017; Mexico City, Mexico.

Lectin pathway effector enzyme mannan-binding lectin-associated serine protease-2 can activate native complement C3 in absence of C4 and/or C2

Yaseen S, Demopulos G, Dudler T, et al. FASEB J. 2017;31(5):2210-2219. doi:10.1096/fj.201601306R.

View on PubMed

Resolution of acute kidney injury secondary to TA-TMA by the anti-MASP-2 monoclonal antibody OMS721 in a pediatric HSCT recipient

Zecca M, Comoli P, Mina T, et al. Bone Marrow Transplantation. 2017;52:S124-S516.
View abstract

2016

Mannan binding lectin-associated serine protease-2 (MASP-2) critically contributes to post-ischemic brain injury independent of MASP-1

Orsini F, Chrysanthou E, Dudler T, et al. J Neuroinflammation. 2016;13(1):213. doi:10.1186/s12974-016-0684-6.

View on PubMed

2014

Mannan-binding lectin-associated serine protease 2 is critical for the development of renal ischemia reperfusion injury and mediates tissue injury in the absence of complement C4

Asgari E, Farrar CA, Lynch N, et al. FASEB J. 2014;28(9):3996-4003.
View on PubMed

2012

The lectin pathway of complement activation is a critical component of the innate immune response to pneumococcal infection

Ali YM, Lynch NJ, Haleem KS, et al. PLoS Pathog. 2012;8:e1002793.
View on PubMed

2011

Targeting of mannan-binding lectin-associated serine protease-2 confers protection from myocardial and gastrointestinal ischemia/reperfusion injury

Schwaeble WJ1, Lynch NJ, Clark JE,et al. Proc Natl Acad Sci USA. 2011;108(18):7523-7528. doi:10.1073/pnas.1101748108.
View on PubMed

2010

Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot

Gulla KC1, Gupta K, Krarup A, et al. Immunology. 2010;129(4):482-495. doi:10.1111/j.1365-2567.2009.03200.x.
View on PubMed

Other Publications:

Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modulation of mesolimbic dopaminergic transmission

Ciccocioppo R, de Guglielmo G, Li H, et al. J Neurosci. 2021;41(28):6128-6143. doi:10.1523/JNEUROSCI.3180-20.2021.
View on PubMed

PPARγ activation attenuates opioid consumption and modulates mesolimbic dopamine transmission

de Guglielmo G, Melis M, De Luca MA, et al. Neuropsychopharmacology. 2015;40(4):927-937. doi:10.1038/npp.2014.268.

View on PubMed

Selection of targeted mutants from a library of randomly mutagenized ES cells

Horie K, Gaitanaris G, Gragerov A. Methods Mol Biol. 2011;693:283-294. doi:10.1007/978-1-60761-974-1_17.

View on PubMed

An inducible and reversible mouse genetic rescue system

Zeng H, Horie K, Madisen L, et al. PLoS Genet. 2008;4(5):e1000069. doi:10.1371/journal.pgen.1000069.

View on PubMed

Neuromedin U receptor 2-deficient mice display differential responses in sensory perception, stress, and feeding

Zeng H, Gragerov A, Hohmann JG, et al. Mol Cell Biol. 2006;26(24):9352-9363.

View on PubMed